|
⚲
|
| Keyboard |
| Ran Nussbaum | |
|---|---|
| Firm | |
| Address | c/o Graviton Bioscience Corporation 125 West End Ave, Suite 301 New York, NY 10023 |
| Source |
| Associated Funds | Form D | Role | 2011 - 2026 | Raised | AUM |
|---|---|---|---|---|---|
| Graviton Bioscience Corp | 021-505280 | Director | 25.0 M of 25.0 M |
||
| Graviton Bioscience Corp | 021-498756 | Director | 25.0 M of 25.0 M |
||
| Graviton Bioscience Corp | 021-498757 | Director | 39.8 M of 50.0 M |
||
| LB Pharmaceuticals Inc | 021-492682 | Director | 110.7 M of 110.7 M |
||
| UroGen Pharma Ltd | 021-489628 | Director | 120.0 M of 120.0 M |
||
| Keros Therapeutics Inc | 021-362700 | Director | 56.0 M of 56.0 M |
||
| Keros Therapeutics Inc | 021-326320 | Director | 11.5 M of 23.0 M |
||
| Keros Therapeutics Inc | 021-262318 | Director | 11.0 M of 11.0 M |
||
| Kite Pharma Inc | 021-216713 | Director | 50.0 M of 50.0 M |
||
| Kite Pharma Inc | 021-197020 | Director | 16.4 M of 16.4 M |
||